Publications
5491 Results
- Journal / Conference
- Journal of the National Cancer Institute May 8;116(5):673-680
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38243705
- PMC
- PMC11077308
- Study Number(s)
- S1609
Correlation Between Tumor Size Change and Outcome in a Rare Cancer Immunotherapy Basket Trial
- Journal / Conference
- Cancer May 15;130(10):1784-1796
- Year
- 2024
- Research Committee(s)
- Melanoma
- PMID
- PMID38261444
- Study Number(s)
- S1221
A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers
- Journal / Conference
- Leukemia Feb;38(2):389-392
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38263433
Clinical Evaluation of Complete Remission (CR) with Partial Hematologic Recovery (CRh) in Acute Myeloid Leukemia: A Report of 7,235 Patients from Seven Cohorts Running head: Survival following CRh in AML
- Journal / Conference
- Cancer Res Commun Feb 16. doi: 10.1158/2767-9764.CRC-22-0516. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38363156
- Study Number(s)
- CTSU/C80802
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma
- Journal / Conference
- JAMA Network Open Jan 2;7(1):e2351062
- Year
- 2024
- Research Committee(s)
- Lymphoma
- PMID
- PMID38241048
- PMC
- PMC10799264
- Study Number(s)
- S1826
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
- Journal / Conference
- Eur J Cancer Feb 10:201:113914. doi: 10.1016/j.ejca.2024.113914. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID: 38359495
- Study Number(s)
- CTSU/C80405
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
- Journal / Conference
- Blood Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38215395
- Study Number(s)
- CTSU/A041202
Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL
- Journal / Conference
- Cancer Feb 15. doi: 10.1002/cncr.35243. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38358334
- Study Number(s)
- S1609
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials
- Journal / Conference
- Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38424319
- Study Number(s)
- S1216